Then, in January, the FDA approved the company's drug Omvoh for Crohn's disease. The drug was first approved in October 2023 for patients with moderately to severely active ulcerative colitis ...

The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B reactivation (HBVr) in at-risk individuals, recommending antiviral prophylaxis for ...

A 5-year-old boy died in an explosion at a medical facility in Troy, Mich., on Friday, Jan. 31, according to the Troy Fire Department. The young child, whose identity has not been revealed, was in a ...

EXTON, PA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The FDA's approval of Eli Lilly’s Omvoh for Crohn’s disease marks a significant milestone as the therapy becomes the second IL-23 inhibitor ...

Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab ...

FRANKFURT (Reuters) - The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization and related programmes risks harming millions of ...

The Food and Drug Administration (FDA) has approved Omvoh ® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults. Mirikizumab is a humanized immunoglobulin G4 ...

Omvoh (mirikizumab-mrkz) has potential interactions with certain vaccines and health conditions. These interactions could cause harmful effects in some people. Omvoh is used in adults to treat ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Wearable devices can identify ...

The senior vice president at Lilly Immunology Development discusses recent developments with Omvoh. The European Medicines Agency’s Committee for Medicinal Products for Human Use recently issued a ...